Login to Your Account

Blue skies for Cerulean? Cancer nanobiotech files for $75M IPO

By Marie Powers
Staff Writer

Monday, March 10, 2014

Despite a phase IIb miss this time last year for lead compound CRLX101 in advanced non-small-cell lung cancer (NSCLC), Cerulean Pharma Inc. vowed to plow forward with its nanopharmaceutical platform. After dosing the first patient last month in a phase II trial of CRLX101, the company is moving ahead in a big way, filing Monday with the SEC to raise up to $75 million in an initial public offering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription